Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Infection Prevention and Control, Sheba Medical Center, Tel Hashomer, Israel, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Isr Med Assoc J. 2024 Jan;26(1):12-17.
Pregnant women are at higher risk for severe coronavirus disease 2019 (COVID-19). Since the release of the BNT162b2 messenger RNA vaccine (Pfizer/BioNTech), there has been accumulated data about the three vaccine doses. However, information regarding obstetric and neonatal outcomes of pregnant women vaccinated with the third (booster) vaccine is limited and primarily retrospective.
To evaluate the obstetric and early neonatal outcomes of pregnant women vaccinated during pregnancy with the COVID-19 booster vaccine compared to pregnant women vaccinated only by the first two doses.
We conducted a cross-sectional study of pregnant women who received the BNT162b2 vaccine during pregnancy. Obstetric and neonatal outcomes were compared between pregnant women who received only the first two doses of the vaccine to those who also received the booster dose.
Overall, 139 pregnant women were vaccinated during pregnancy with the first two doses of the vaccine and 84 with the third dose. The third dose group received the vaccine earlier during their pregnancy compared to the two doses group (212 vs. 315 weeks, respectively, P < 0.001). No differences in obstetric and early neonatal outcomes between the groups were found except for lower rates of urgent cesarean delivery in the third dose group (adjusted odds ratio 0.21; 95% confidence interval 0.048-0.926, P = 0.039).
Compared to the first two doses of the BNT162b2 vaccine given in pregnancy, the booster vaccination is safe and not associated with an increased rate of adverse obstetric and early neonatal outcomes.
孕妇感染 2019 年冠状病毒病（COVID-19）的重症风险较高。自 BNT162b2 信使 RNA 疫苗（辉瑞/生物科技）发布以来，已有关于该疫苗三剂接种的数据积累。然而，关于接种第三剂（加强针）疫苗的孕妇的产科和新生儿结局的信息有限，且主要为回顾性研究。
评估与仅接种前两剂疫苗的孕妇相比，妊娠期间接种 COVID-19 加强针疫苗的孕妇的产科和早期新生儿结局。
我们进行了一项关于妊娠期间接种 BNT162b2 疫苗的孕妇的病例对照研究。比较仅接种前两剂疫苗的孕妇与接种第三剂疫苗的孕妇的产科和新生儿结局。
共有 139 名孕妇在妊娠期间接种了前两剂疫苗，84 名孕妇接种了第三剂疫苗。与两剂组相比，第三剂组在妊娠期间更早地接种了疫苗（分别为 212 周和 315 周，P<0.001）。两组之间在产科和早期新生儿结局方面没有差异，除了第三剂组的紧急剖宫产率较低（调整后的优势比 0.21；95%置信区间 0.048-0.926，P=0.039）。
与妊娠期间接种的 BNT162b2 疫苗的前两剂相比，加强针接种是安全的，不会增加不良产科和新生儿早期结局的风险。
